F. Pagès, A. Berger, and M. Camus, Effector memory T cells, early metastasis, and survival in colorectal cancer, N Eng J Med, vol.353, pp.2654-66, 2005.

J. Galon, Type, density, and location of immune cells within human colorectal tumors predict clinical outcome, Science, vol.313, pp.1960-1964, 2006.

C. Reissfelder, S. Stamova, and C. Gossmann, Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis, J Clin Invest, vol.125, pp.1364-1364, 2015.

F. Pagès, B. Mlecnik, and F. Marliot, International validation of the consensus immunoscore for the classification of colon cancer: a prognostic and accuracy study, Lancet, vol.391, pp.2128-2167, 2018.

B. Mlecnik, G. Bindea, and H. K. Angell, Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability, Immunity, vol.44, pp.698-711, 2016.

A. Banerjea, R. E. Hands, and M. P. Powar, Microsatellite and chromosomal stable colorectal cancers demonstrate poor immunogenicity and early disease recurrence, Colorectal Dis, vol.11, pp.601-609, 2009.

J. Guinney, R. Dienstmann, and X. Wang, The consensus molecular subtypes of colorectal cancer, Nat Med, vol.21, pp.1350-1356, 2015.

L. Marisa, A. De-reyniès, and A. Duval, Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value, PLoS Med, vol.10, p.1001453, 2013.

N. J. Llosa, M. Cruise, and A. Tam, The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints, Cancer Discov, vol.5, pp.43-51, 2015.

E. Ott, L. Bilonda, and D. Dansette, The density of Tbet+ tumorinfiltrating T lymphocytes reflects an effective and druggable preexisting adaptive antitumor immune response in colorectal cancer, irrespective of the microsatellite status, OncoImmunology, vol.8, p.1562834, 2019.
URL : https://hal.archives-ouvertes.fr/inserm-02100125

J. Wischhusen, M. A. Friese, and M. Mittelbronn, HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: implications for immune escape in vivo, J Neuropathol Exp Neurol, vol.64, pp.523-531, 2005.

L. Derré, M. Corvaisier, and B. Charreau, Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells, J Immunol, vol.177, pp.3100-3107, 2006.

E. M. Levy, M. Bianchini, V. Euw, and E. M. , Human leukocyte antigen-E protein is overexpressed in primary human colorectal cancer, Int J Oncol, vol.32, pp.633-674, 2008.

V. M. Braud, D. Allan, and C. A. O'callaghan, HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C, Nature, vol.391, pp.795-804, 1998.

F. Borrego, M. Masilamani, and A. I. Marusina, The CD94/NKG2 family of receptors: from molecules and cells to clinical relevance, Immunol Res, vol.35, pp.263-78, 2006.

C. Bossard, S. Bézieau, and T. Matysiak-budnik, HLA-E/?2 microglobulin overexpression in colorectal cancer is associated with recruitment of inhibitory immune cells and tumor progression, Int J Cancer, vol.131, pp.855-63, 2012.

R. Wang, M. Wang, and P. J. , Clinicopathological features and survival outcomes of colorectal cancer in young versus elderly: a population-based cohort study of SEER 9 registries data, Medicine, vol.94, p.1402, 1988.

N. Suraweera, A. Duval, and M. Reperant, Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR, Gastroenterol, vol.123, pp.1804-1815, 2002.

A. Umar, C. R. Boland, and J. P. Terdiman, Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability, J Natl Cancer Inst, vol.96, pp.261-269, 2004.

N. Gervois, N. Labarriere, L. Guiner, and S. , High avidity melanoma-reactive cytotoxic T lymphocytes are efficiently induced from peripheral blood lymphocytes on stimulation by peptidepulsed melanoma cells, Clin Cancer Res, vol.6, pp.1459-67, 2000.

M. S. Lee, D. G. Menter, and S. Kopetz, Right versus left colon cancer biology: integrating the consensus molecular subtypes, J Natl Compr Canc Netw, vol.15, pp.411-420, 2017.

J. N. Mandrekar, S. J. Mandrekar, and S. S. Cha, Cutpoint determination methods in survival analysis using SAS®, Proceedings of the 28th SAS Users Group International Conference (SUGI) 2003, pp.261-289

P. André, C. Denis, and C. Soulas, Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells, Br J Cancer, vol.175, pp.459-68, 2014.

M. Gooden, M. Lampen, and E. S. Jordanova, HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+ T lymphocytes, Proc Natl Acad Sci USA, vol.108, pp.10656-61, 2011.

M. Gooden and T. Van-hall, Infiltrating CTLs are bothered by HLA-E on tumors, Oncoimmunol, vol.1, pp.92-95, 2012.

N. Van-montfoort, L. Borst, and M. J. Korrer, NKG2A blockade potentiates CD8 T cell immunity induced by cancer vaccines, Cell, vol.175, pp.1744-1755, 2018.

N. Halama, M. Braun, and C. Kahlert, Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines, Clin Cancer Res, vol.17, pp.678-89, 2011.

B. Sheu, S. Chiou, and H. Lin, Up-regulation of inhibitory natural killer receptors CD94/NKG2A with suppressed intracellular perforin expression of tumor-infiltrating CD8+ T lymphocytes in human cervical carcinoma, Cancer Res, vol.65, pp.2921-2930, 2005.

W. Chang, S. Huang, and P. Torng, Expression of inhibitory natural killer receptors on tumor-infiltrating CD8+ T lymphocyte lineage in human endometrial carcinoma, Int J Gynecol Cancer, vol.15, pp.1073-80, 2005.

L. Zhang, Y. Zhao, and Y. Dai, Immune landscape of colorectal cancer tumor microenvironment from different primary tumor location, Front Immunol, vol.9, p.1578, 2018.

K. Malmberg, V. Levitsky, and H. Norell, IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism, J Clin Invest, vol.110, pp.1515-1538, 2002.

D. Chen, L. Li, and X. Zhang, FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: a meta-analysis, Medicine, vol.97, p.97, 2018.

C. Service-d'anatomie and . Pathologiques,

, LabEx IGO "Immunotherapy, Graft, Oncology

, Institut des Maladies de l'Appareil Digestif, Oncologie Digestive